Curis stock jumps 11% on positive emavusertib trial data By Investing.com

Curis, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.

Original reporting
Published Jul 22, 2026, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 12:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CRIS
Bullish
medium confidence
Mentioned
$CRIS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CRISBullishMed
01

Why it matters

Updated TakeAim Lymphoma efficacy results and increased CLL enrollment guidance are likely to drive a reassessment of clinical/regulatory probability and near-term cash burn expectations tied to trial progression.

02

Market read

Traders can use the specific ORR figures and the revised year-end CLL enrollment range (5 to 5-10 patients) as fresh catalysts for biotech positioning and options pricing.

03

What to watch

The article does not provide safety/tolerability, duration of response, progression-free survival, or interim endpoints for PCNSL/CLL, which can materially affect valuation even with higher ORR.

Relevance 8/10Novelty 7/10Timing: today’s premarket/Wednesday session reaction to updated trial data and revised CLL enrollment guidance

Background

Curis is developing emavusertib, an orally available IRAK4 and FLT3 inhibitor, in combination with BTK inhibitors across PCNSL and CLL studies.

Company-level read

Ticker impact

$CRISBullishMedium confidence
Context

Curis shares jumped 11% after updated emavusertib TakeAim Lymphoma data showed 86% ORR in BTK inhibitor-naive PCNSL patients and raised CLL enrollment guidance.

Expected impact

Bullish bias for the next several sessions, with follow-through dependent on further trial updates and FDA/EMA discussions.

Evidence & confidence

The article provides specific response-rate figures, patient subgroups, and a concrete year-end enrollment guidance increase, which are direct catalysts for biotech risk/reward repricing.

Market effects

Reinforces investor appetite for IRAK4/FLT3 inhibitor strategies in lymphoma/CLL combinations, potentially lifting sentiment for similar clinical-stage oncology names.

Limited, primarily US small-cap biotech sentiment.

Moderate, as FDA/EMA guidance context is referenced but no cross-border regulatory decision is reported.

Counterpoint

Response rates may not translate into durable outcomes or accelerated-approval eligibility; small sample sizes and subgroup imbalance can exaggerate early efficacy.

Key entities

  • Curis, Inc.

    NASDAQ-listed biotech whose emavusertib trial updates drove an 11% stock move.

  • Emavusertib

    Orally available IRAK4 and FLT3 inhibitor being tested with BTK inhibitors in PCNSL and CLL.

  • FDA and EMA

    Meetings completed in 2025 with guidance suggesting the ongoing study could support accelerated approval in Relapsed/Refractory PCNSL.

Related articles

$CRISHigh

Curis Provides Third Quarter 2026 Business Update

CURIS INC (CRIS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2026 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of

$CRISMed

Curis (CRIS) Q3 2026 Earnings Call Transcript

Curis (CRIS) reported Q3 2026 net loss of $8.1M, narrower than 2025. The company is advancing clinical trials for emavusertib in NHL and CLL, with initial data expected by year-end. They aim for accelerated approval submissions in 2027. Cash reserves are $5M, expected to fund operations into 2027.

$CRISMedAI 8/10

Curis Provides Third Quarter 2026 Business Update

Curis, Inc. (CRIS) reported Q3 2026 financial results, showing a net loss of $8.1M, and provided a business update. The company is conducting studies on emavusertib for CLL and PCNSL, with initial data expected in December 2026. Curis completed a public offering and a private placement, extending its cash runway into 2027. Management will host a conference call to discuss the update.

$CRISMedAI 8/10

Curis Prices $5.6 Million Offering Of Shares And Warrants; Stock Up

Curis, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).

$CRISMed

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.

$CRISMedAI 8/10

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Curis (NASDAQ:C

Curis Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.